diff --git a/domains/health/GLP-1 receptor agonists are the largest therapeutic category launch in pharmaceutical history but their chronic use model makes the net cost impact inflationary through 2035.md b/domains/health/GLP-1 receptor agonists are the largest therapeutic category launch in pharmaceutical history but their chronic use model makes the net cost impact inflationary through 2035.md index 377f3150e..b3a89e2dd 100644 --- a/domains/health/GLP-1 receptor agonists are the largest therapeutic category launch in pharmaceutical history but their chronic use model makes the net cost impact inflationary through 2035.md +++ b/domains/health/GLP-1 receptor agonists are the largest therapeutic category launch in pharmaceutical history but their chronic use model makes the net cost impact inflationary through 2035.md @@ -61,22 +61,28 @@ The Trump Administration's Medicare GLP-1 deal establishes $245/month pricing (8 ### Additional Evidence (challenge) -*Source: [[2025-07-01-sarcopenia-glp1-muscle-loss-elderly-risk]] | Added: 2026-03-16* +*Source: 2025-07-01-sarcopenia-glp1-muscle-loss-elderly-risk | Added: 2026-03-16* The sarcopenic obesity mechanism creates a pathway where GLP-1s may INCREASE healthcare costs in elderly populations: muscle loss during treatment + high discontinuation (64.8% at 1 year) + preferential fat regain = sarcopenic obesity → increased fall risk, fractures, disability, and long-term care needs. This directly challenges the Medicare cost-savings thesis by creating NEW healthcare costs (disability, falls, fractures) that may offset cardiovascular and metabolic savings. ### Additional Evidence (extend) -*Source: [[2025-12-01-who-glp1-global-guidelines-obesity]] | Added: 2026-03-16* +*Source: 2025-12-01-who-glp1-global-guidelines-obesity | Added: 2026-03-16* WHO issued conditional recommendations (not full endorsements) for GLP-1s in obesity treatment, explicitly acknowledging 'limited long-term evidence.' The conditional framing signals institutional uncertainty about durability of outcomes and cost-effectiveness at population scale. WHO requires countries to 'consider local cost-effectiveness, budget impact, and ethical implications' before adoption, suggesting the chronic use economics remain unproven for resource-constrained health systems. ### Additional Evidence (challenge) -*Source: [[2025-01-01-jmir-digital-engagement-glp1-weight-loss-outcomes]] | Added: 2026-03-16* +*Source: 2025-01-01-jmir-digital-engagement-glp1-weight-loss-outcomes | Added: 2026-03-16* Danish cohort achieved same weight loss outcomes (16.7% at 64 weeks) using HALF the typical semaglutide dose when paired with digital behavioral support, matching clinical trial results at 50% drug cost. If this half-dose protocol proves generalizable, it could fundamentally alter the inflationary cost trajectory by reducing per-patient drug spending while maintaining efficacy. + +### Additional Evidence (challenge) +*Source: [[2026-03-01-glp1-lifestyle-modification-efficacy-combined-approach]] | Added: 2026-03-16* + +If GLP-1+exercise combination produces durable behavioral change that persists after medication discontinuation (3.5 kg regain vs 8.7 kg for medication alone), then the chronic use model may not be necessary for value creation. The inflationary cost impact assumes indefinite medication use, but combination therapy with time-limited medication plus sustained behavioral change could alter the economic trajectory. + --- Relevant Notes: diff --git a/domains/health/glp-1-persistence-drops-to-15-percent-at-two-years-for-non-diabetic-obesity-patients-undermining-chronic-use-economics.md b/domains/health/glp-1-persistence-drops-to-15-percent-at-two-years-for-non-diabetic-obesity-patients-undermining-chronic-use-economics.md index 518add3b8..2ff8b7b8d 100644 --- a/domains/health/glp-1-persistence-drops-to-15-percent-at-two-years-for-non-diabetic-obesity-patients-undermining-chronic-use-economics.md +++ b/domains/health/glp-1-persistence-drops-to-15-percent-at-two-years-for-non-diabetic-obesity-patients-undermining-chronic-use-economics.md @@ -55,16 +55,22 @@ The $50/month out-of-pocket maximum for Medicare beneficiaries (starting April 2 ### Additional Evidence (extend) -*Source: [[2025-07-01-sarcopenia-glp1-muscle-loss-elderly-risk]] | Added: 2026-03-16* +*Source: 2025-07-01-sarcopenia-glp1-muscle-loss-elderly-risk | Added: 2026-03-16* The discontinuation problem is worse than just lost metabolic benefits - it creates a body composition trap. Patients who discontinue lose 15-40% of weight as lean mass during treatment, then regain weight preferentially as fat without muscle recovery. This means the most common outcome (discontinuation) leaves patients with WORSE body composition than baseline: same or higher fat, less muscle, higher disability risk. Weight cycling on GLP-1s is not neutral - it's actively harmful. ### Additional Evidence (extend) -*Source: [[2025-01-01-jmir-digital-engagement-glp1-weight-loss-outcomes]] | Added: 2026-03-16* +*Source: 2025-01-01-jmir-digital-engagement-glp1-weight-loss-outcomes | Added: 2026-03-16* Digital behavioral support may partially solve the persistence problem: UK study showed 11.53% weight loss with engagement vs 8% without at 5 months, suggesting the adherence paradox has a behavioral solution component. However, high withdrawal rates in non-engaged groups suggest this requires active participation, not passive app access. + +### Additional Evidence (extend) +*Source: [[2026-03-01-glp1-lifestyle-modification-efficacy-combined-approach]] | Added: 2026-03-16* + +Weight regain data shows GLP-1 alone produces 8.7 kg regain versus 3.5 kg for GLP-1+exercise combination, suggesting low persistence may not be the primary problem—even continuous use without behavioral support may not produce durable outcomes. The 15% persistence rate may reflect patients discovering the medication alone doesn't create lasting change. + --- Relevant Notes: diff --git a/domains/health/lower-income-patients-show-higher-glp-1-discontinuation-rates-suggesting-affordability-not-just-clinical-factors-drive-persistence.md b/domains/health/lower-income-patients-show-higher-glp-1-discontinuation-rates-suggesting-affordability-not-just-clinical-factors-drive-persistence.md index b9259e3a0..839618ff3 100644 --- a/domains/health/lower-income-patients-show-higher-glp-1-discontinuation-rates-suggesting-affordability-not-just-clinical-factors-drive-persistence.md +++ b/domains/health/lower-income-patients-show-higher-glp-1-discontinuation-rates-suggesting-affordability-not-just-clinical-factors-drive-persistence.md @@ -39,10 +39,16 @@ The source does not provide granular income-stratified discontinuation rates, so ### Additional Evidence (confirm) -*Source: [[2025-11-06-trump-novo-lilly-glp1-price-deals-medicare]] | Added: 2026-03-16* +*Source: 2025-11-06-trump-novo-lilly-glp1-price-deals-medicare | Added: 2026-03-16* The Trump Administration deal establishes a $50/month out-of-pocket maximum for Medicare beneficiaries, explicitly targeting affordability as a persistence barrier. The $245/month Medicare price (down from ~$1,350) combined with the OOP cap is designed to address the affordability-driven discontinuation pattern observed in lower-income populations. + +### Additional Evidence (extend) +*Source: [[2026-03-01-glp1-lifestyle-modification-efficacy-combined-approach]] | Added: 2026-03-16* + +Exercise-containing interventions show 2.5x better weight maintenance than medication alone (3.5 kg vs 8.7 kg regain), suggesting discontinuation may be less problematic if patients received structured exercise support during treatment. Lower-income discontinuation may be economically rational if medication-only approach produces no durable benefit. + --- Relevant Notes: diff --git a/inbox/archive/.extraction-debug/2026-03-01-glp1-lifestyle-modification-efficacy-combined-approach.json b/inbox/archive/.extraction-debug/2026-03-01-glp1-lifestyle-modification-efficacy-combined-approach.json new file mode 100644 index 000000000..5cea0c674 --- /dev/null +++ b/inbox/archive/.extraction-debug/2026-03-01-glp1-lifestyle-modification-efficacy-combined-approach.json @@ -0,0 +1,26 @@ +{ + "rejected_claims": [ + { + "filename": "glp-1-combined-with-structured-exercise-prevents-weight-regain-through-behavioral-change-not-pharmacological-persistence.md", + "issues": [ + "missing_attribution_extractor" + ] + } + ], + "validation_stats": { + "total": 1, + "kept": 0, + "fixed": 3, + "rejected": 1, + "fixes_applied": [ + "glp-1-combined-with-structured-exercise-prevents-weight-regain-through-behavioral-change-not-pharmacological-persistence.md:set_created:2026-03-16", + "glp-1-combined-with-structured-exercise-prevents-weight-regain-through-behavioral-change-not-pharmacological-persistence.md:stripped_wiki_link:glp-1-persistence-drops-to-15-percent-at-two-years-for-non-d", + "glp-1-combined-with-structured-exercise-prevents-weight-regain-through-behavioral-change-not-pharmacological-persistence.md:stripped_wiki_link:GLP-1 receptor agonists are the largest therapeutic category" + ], + "rejections": [ + "glp-1-combined-with-structured-exercise-prevents-weight-regain-through-behavioral-change-not-pharmacological-persistence.md:missing_attribution_extractor" + ] + }, + "model": "anthropic/claude-sonnet-4.5", + "date": "2026-03-16" +} \ No newline at end of file diff --git a/inbox/archive/2026-03-01-glp1-lifestyle-modification-efficacy-combined-approach.md b/inbox/archive/2026-03-01-glp1-lifestyle-modification-efficacy-combined-approach.md index 3c5435d24..811c74ca7 100644 --- a/inbox/archive/2026-03-01-glp1-lifestyle-modification-efficacy-combined-approach.md +++ b/inbox/archive/2026-03-01-glp1-lifestyle-modification-efficacy-combined-approach.md @@ -7,9 +7,13 @@ date: 2026-03-01 domain: health secondary_domains: [] format: review -status: unprocessed +status: enrichment priority: high tags: [glp-1, lifestyle-modification, exercise, sarcopenia, muscle-preservation, adherence, weight-regain, obesity] +processed_by: vida +processed_date: 2026-03-16 +enrichments_applied: ["glp-1-persistence-drops-to-15-percent-at-two-years-for-non-diabetic-obesity-patients-undermining-chronic-use-economics.md", "GLP-1 receptor agonists are the largest therapeutic category launch in pharmaceutical history but their chronic use model makes the net cost impact inflationary through 2035.md", "lower-income-patients-show-higher-glp-1-discontinuation-rates-suggesting-affordability-not-just-clinical-factors-drive-persistence.md"] +extraction_model: "anthropic/claude-sonnet-4.5" --- ## Content @@ -75,3 +79,11 @@ Synthesis of 2025-2026 research on combining lifestyle modifications (diet, exer PRIMARY CONNECTION: GLP-1 cost-effectiveness under capitation requires solving the adherence paradox (March 12 claim candidate) WHY ARCHIVED: The "exercise is the active ingredient for weight maintenance" finding significantly changes how to evaluate BALANCE model design and GLP-1 economic models under VBC EXTRACTION HINT: Focus on the GLP-1 alone vs. GLP-1+exercise regain comparison — this is the claim-worthy finding. Also note the BALANCE model design needs evaluation against this evidence. + + +## Key Facts +- Meta-analysis of 22 RCTs with 2,258 participants found ~25% of GLP-1 weight loss is lean mass +- Without exercise, 15-40% of GLP-1 weight loss is lean mass; with resistance training this is substantially reduced +- Up to 50% of adults over 80 experience sarcopenia; aging reduces muscle mass 12-16% baseline +- WHO December 2025 guidelines recommend GLP-1 'combined with intensive behavioral therapy' +- No FDA-approved GLP-1 compounds with proven muscle preservation yet; tirzepatide may have better profile than semaglutide (preliminary)